GeneHealth - Your precision medicine

Dilated Cardiomyopathy 1aa

Disease Details

Family Health Simplified

Buy Membership

Description: Dilated cardiomyopathy 1A (DCM1A) is a type of genetic disorder characterized by the enlargement and weakening of the heart's left ventricle, which impairs the heart's ability to pump blood efficiently.

One-sentence description: Dilated cardiomyopathy 1A is a genetic condition that causes the left ventricle of the heart to enlarge and weaken, leading to impaired cardiac function.
Type: Dilated cardiomyopathy 1AA (DCM1AA) is an autosomal dominant genetic disorder.
Signs And Symptoms: Dilated cardiomyopathy (DCM) often presents with the following signs and symptoms:

1. Shortness of breath, especially during exertion or when lying down.
2. Fatigue and weakness.
3. Swelling in the legs, ankles, feet, abdomen, or veins in the neck.
4. Irregular heartbeats (arrhythmias).
5. Dizziness, lightheadedness, or fainting.
6. Reduced ability to exercise.
7. Chest pain or discomfort.

"Nan" typically denotes not a number or could be a data placeholder; it’s unclear in this context. If you meant to ask for specific numerical values, please provide more precise details.
Prognosis: Dilated cardiomyopathy type 1A (DCM1A) is a genetic disorder affecting the heart muscle, leading to its dilation and weakening, which impairs its ability to pump blood effectively. The prognosis for individuals with DCM1A can vary widely depending on the severity and progression of the disease, the presence of symptoms, and the appropriateness of treatment.

Management usually involves medications to improve heart function, lifestyle changes, and, in some cases, devices like implantable cardioverter-defibrillators (ICDs) or heart transplant.

"nan" may imply missing information or data, so if you meant something specific by "nan," please clarify for a more accurate response.
Onset: Dilated cardiomyopathy-1A (DCM1A) typically manifests in adulthood, usually between the ages of 20 and 50. The condition is characterized by the dilation and impaired contraction of the left ventricle or both ventricles.
Prevalence: The term "dilated cardiomyopathy 1AA" appears to refer to a specific genetic form of dilated cardiomyopathy. Dilated cardiomyopathy (DCM) generally has an estimated prevalence of about 1 in 250 individuals in the general population. However, the prevalence of specific genetic forms like dilated cardiomyopathy 1AA can vary and is generally rare, with detailed prevalences often not well-defined in the literature due to their specific and uncommon nature.
Epidemiology: Dilated cardiomyopathy (DCM) is the most common type of cardiomyopathy, characterized by the enlargement and impaired contraction of the left ventricle. Epidemiologically, DCM has a prevalence rate of approximately 1 in 250 to 1 in 500 in the general population. It affects individuals of all ages but is most frequently diagnosed in middle-aged adults. DCM is slightly more common in men compared to women. The condition can be idiopathic or result from various causes, including genetic mutations, infections, toxins, and metabolic disorders. Genetic factors play a significant role, with familial cases accounting for up to 30-50% of DCM diagnoses.
Intractability: Dilated cardiomyopathy (DCM) is a condition that affects the heart muscle, leading to an enlarged and weakened heart that cannot pump blood efficiently. While the disease itself may not be fully curable, it is not necessarily intractable. Management options can include medications, lifestyle changes, and potentially devices such as pacemakers or defibrillators, and in severe cases, heart transplantation. These treatments can help manage symptoms, improve quality of life, and slow the progression of the disease.
Disease Severity: Dilated cardiomyopathy 1AA (DCM1AA) is a form of dilated cardiomyopathy, a condition characterized by an enlarged and weakened left ventricle, which impairs the heart's ability to pump blood efficiently. The severity of DCM1AA can vary widely among individuals. It can be mild, presenting with minimal symptoms, or severe, leading to significant heart failure and, potentially, life-threatening complications such as arrhythmias or sudden cardiac death. Regular monitoring and management by a healthcare professional are crucial for assessing and addressing disease progression in individuals with DCM1AA.
Healthcare Professionals: Disease Ontology ID - DOID:0110428
Pathophysiology: Dilated cardiomyopathy type 1A (DCM1A) is a genetic form of dilated cardiomyopathy, primarily associated with mutations in the LMNA gene, which encodes lamins A and C, crucial components of the nuclear envelope. The pathophysiology of DCM1A involves:

1. **Genetic Mutation**: Mutations in the LMNA gene lead to abnormal lamin A/C proteins, which compromise the structural integrity and function of the nuclear envelope.

2. **Nuclear Envelope Dysfunction**: This results in increased susceptibility to mechanical stress and cellular damage, particularly in cardiac muscle cells (cardiomyocytes).

3. **Cardiomyocyte Damage**: Over time, the damaged cardiomyocytes undergo apoptosis or necrosis, leading to thinning and weakening of the cardiac muscle.

4. **Chamber Dilation**: The heart chambers, especially the left ventricle, become dilated to maintain cardiac output despite weakened muscle, leading to a dilated heart appearance.

5. **Impaired Pump Function**: As the myocardium's contractile function declines, the heart's pumping efficiency diminishes, causing symptoms of heart failure and systemic circulatory issues.

The overall result is a progressive decline in cardiac function, manifesting clinically as heart failure, arrhythmias, and other cardiovascular complications.
Carrier Status: Dilated cardiomyopathy 1A (DCM1A) is associated with mutations in the LMNA gene, which encodes lamin A/C proteins. Carriers of a single mutated LMNA gene (heterozygous carriers) may develop symptoms of dilated cardiomyopathy, while individuals with two normal copies of the gene (non-carriers) typically do not exhibit the disease. The disease is inherited in an autosomal dominant manner, meaning that one copy of the mutated gene is sufficient to increase the risk of developing the condition.
Mechanism: Dilated cardiomyopathy (DCM) is a condition characterized by an enlarged and weakened heart muscle, particularly affecting the left ventricle. The heart's ability to pump blood is diminished, which can lead to heart failure and other complications.

**Mechanism:**
In DCM, the dilation or enlargement of the heart chambers reduces the efficiency of blood pumping. The heart muscle becomes stretched and thinner, leading to impaired contractility. This reduced contractile function means less blood is ejected with each heartbeat. Over time, this inefficiency can result in fluid buildup in the lungs, abdomen, and lower extremities, contributing to symptoms such as shortness of breath, fatigue, and swelling.

**Molecular Mechanisms:**
1. **Genetic Mutations:**
- DCM can be caused by mutations in various genes encoding proteins necessary for the structure, function, and regulation of cardiac muscle cells. Common genes implicated include those encoding sarcomeric proteins (e.g., MYH7, which encodes beta-myosin heavy chain) and cytoskeletal proteins (e.g., TTN, which encodes titin).

2. **Sarcomere Dysfunction:**
- Mutations affecting sarcomeric proteins can disrupt the contractile apparatus of the heart muscle cells, weakening their ability to contract forcefully and efficiently. This leads to the characteristic dilation and impaired function seen in DCM.

3. **Cytoskeletal and Extracellular Matrix Defects:**
- The integrity of the cell's cytoskeleton and the extracellular matrix is vital for maintaining the structural integrity and mechanical stability of the heart muscle. Defects here can compromise these support structures, leading to mechanical dysfunction and subsequent dilation.

4. **Calcium Handling Abnormalities:**
- Proper calcium cycling is crucial for cardiac muscle contraction and relaxation. Abnormalities in calcium handling proteins (e.g., phospholamban or SERCA2a) can impair contractility, contributing to the pathogenesis of DCM.

5. **Mitochondrial Dysfunction:**
- As the heart is highly reliant on energy, mutations that impact mitochondrial function can lead to an energy deficiency in cardiac cells. This energy deficit can reduce contractile efficiency and promote heart muscle deterioration.

6. **Autoimmune and Inflammatory Responses:**
- In some cases, autoimmune mechanisms and chronic inflammation can contribute to DCM by damaging cardiac cells and altering the heart's structure and function.

Understanding these molecular mechanisms is critical for developing targeted therapies and improving patient outcomes in DCM.
Treatment: Treatment for dilated cardiomyopathy (DCM) often focuses on managing symptoms and slowing disease progression. Key approaches include:

1. **Medications**:
- **ACE inhibitors** or **ARBs** to lower blood pressure and reduce heart stress.
- **Beta-blockers** to slow heart rate and improve heart function.
- **Diuretics** to remove excess fluid and reduce swelling.
- **Aldosterone antagonists** to prevent sodium retention and further heart damage.
- **Anticoagulants** to prevent blood clots in certain cases.

2. **Device Therapy**:
- **Implantable Cardioverter-Defibrillators (ICDs)** for preventing sudden cardiac death.
- **Cardiac Resynchronization Therapy (CRT)** for coordinating heartbeats in those with heart failure.

3. **Lifestyle Changes**:
- Healthy diet.
- Regular but monitored exercise.
- Avoidance of alcohol and illicit drugs.
- Management of contributing conditions like diabetes and high blood pressure.

4. **Surgery**:
- **Left Ventricular Assist Devices (LVADs)** for severe cases.
- **Heart Transplant** for end-stage disease when other treatments fail.

It's essential to work closely with a healthcare provider to tailor the treatment plan to individual needs.
Compassionate Use Treatment: For dilated cardiomyopathy (DCM) with the specific genetic subtype dilated cardiomyopathy 1A (DCM1A), compassionate use treatments and off-label or experimental treatments may include:

1. **Gene Therapy:** Although still largely experimental, gene therapy aims to correct the underlying genetic mutations causing DCM1A.

2. **Myosin Modulators:** Drugs like omecamtiv mecarbil, which improve cardiac contractility, are being investigated in clinical trials.

3. **Beta-Blockers:** While not specifically approved for DCM1A, beta-blockers such as carvedilol are commonly used off-label to manage symptoms and improve heart function.

4. **Angiotensin-Converting Enzyme (ACE) Inhibitors:** Drugs like enalapril and lisinopril are also used off-label to help reduce the workload on the heart.

5. **Angiotensin II Receptor Blockers (ARBs):** Medications such as losartan can be used off-label for patients who do not tolerate ACE inhibitors.

6. **ARNIs (Angiotensin Receptor-Neprilysin Inhibitors):** Sacubitril/valsartan is another option that may be used off-label to improve outcomes in heart failure.

7. **Cardiac Resynchronization Therapy (CRT):** This device therapy can be considered for patients with evidence of electrical dyssynchrony to improve cardiac function.

8. **Mechanical Circulatory Support:** Devices such as left ventricular assist devices (LVADs) can be used in advanced cases where patients are awaiting heart transplantation.

Each of these treatments should be considered in consultation with a healthcare provider specialized in cardiomyopathies to ensure the best possible care for the individual patient.
Lifestyle Recommendations: ### Lifestyle Recommendations for Dilated Cardiomyopathy (DCM):

1. **Medication Adherence:**
- Consistently take prescribed medications to manage symptoms and prevent complications.

2. **Diet:**
- Follow a low-sodium diet to reduce fluid retention and decrease the workload on the heart.
- Limit alcohol intake as it can exacerbate heart conditions.
- Eat a heart-healthy diet rich in fruits, vegetables, lean proteins, and whole grains.

3. **Exercise:**
- Engage in moderate-intensity exercise as recommended by your healthcare provider.
- Avoid strenuous activities that may overexert the heart.

4. **Weight Management:**
- Maintain a healthy weight to reduce the strain on your heart.

5. **Fluid Management:**
- Monitor and possibly limit fluid intake, following your doctor's recommendations.

6. **Stress Management:**
- Practice stress-reducing techniques such as yoga, meditation, and deep-breathing exercises.
- Ensure adequate rest and sleep.

7. **Regular Health Check-ups:**
- Schedule regular appointments with your cardiologist to monitor your heart function and adjust treatments as necessary.

8. **Avoid Smoking:**
- Quit smoking and avoid secondhand smoke, as smoking can worsen heart failure.

9. **Monitor Symptoms:**
- Be vigilant about recognizing and reporting symptoms such as increased shortness of breath, swelling, and sudden weight gain to your healthcare provider.

10. **Vaccinations:**
- Stay up-to-date with vaccinations (e.g., flu and pneumonia) to prevent infections that can stress the heart.

Personalized recommendations should always be discussed with a healthcare provider specialized in managing dilated cardiomyopathy.
Medication: For dilated cardiomyopathy (DCM), treatment typically focuses on managing symptoms, improving heart function, and addressing the underlying cause. Common medications used include:

1. **ACE Inhibitors (e.g., enalapril, lisinopril)**: Help relax blood vessels and improve blood flow.
2. **Beta-blockers (e.g., carvedilol, metoprolol)**: Reduce the heart's workload and help it beat more regularly.
3. **Diuretics (e.g., furosemide, spironolactone)**: Help remove excess fluid from the body.
4. **Anticoagulants (e.g., warfarin)**: Prevent blood clots if there is a risk of complications like atrial fibrillation.
5. **Anti-arrhythmic medications**: Control abnormal heart rhythms.

Management may also include lifestyle changes, implantable devices, or, in severe cases, a heart transplant. Always consult a healthcare provider for treatment tailored to individual needs.
Repurposable Drugs: Repurposable drugs for dilated cardiomyopathy (DCM) include:

1. **Beta-blockers**: These reduce heart rate and blood pressure, which helps to improve heart function. Common examples are carvedilol and metoprolol.

2. **ACE Inhibitors**: These help relax blood vessels, making it easier for the heart to pump blood. Examples include enalapril and lisinopril.

3. **Angiotensin II Receptor Blockers (ARBs)**: Similar to ACE inhibitors, they help relax blood vessels. Examples are losartan and valsartan.

4. **Aldosterone Antagonists**: These help reduce fluid build-up and improve heart function, with spironolactone and eplerenone being common examples.

5. **Diuretics**: These help remove excess fluid from the body, improving symptoms. Furosemide is a commonly used diuretic.

6. **Ivabradine**: This specifically lowers heart rate and is used for patients who cannot tolerate beta-blockers or need additional heart rate control.

Always consult a healthcare provider for personalized medical advice and treatment options.
Metabolites: Dilated cardiomyopathy is characterized by the dilation and impaired contraction of the left or both ventricles of the heart. Commonly associated metabolites include:

1. **Carnitine**: Low levels can be linked to insufficient energy production in heart muscles.
2. **Coenzyme Q10 (Ubiquinone)**: Seen in deficits, leading to compromised mitochondrial function.
3. **Amino Acids**: Abnormal levels, especially taurine, may indicate disrupted metabolic processes.
4. **Lactate**: Elevated levels can signify anaerobic metabolism due to impaired cardiac output.

Monitoring these metabolites can provide insights into the metabolic disturbances involved in the pathophysiology of the disease.
Nutraceuticals: Dilated cardiomyopathy type 1A (DCM1A) is a genetic disorder characterized by the dilation and impaired contraction of the left ventricle or both ventricles. Nutraceuticals, which are food-derived products that offer health benefits, might play a supportive role in managing this condition, although they cannot replace conventional medical treatment. Some common nutraceuticals that may support heart health include:

1. **Omega-3 Fatty Acids**: Found in fish oil and flaxseed, these have anti-inflammatory properties and can help improve heart function.
2. **Coenzyme Q10 (CoQ10)**: An antioxidant that supports energy production in heart cells and may improve heart function.
3. **L-Carnitine**: An amino acid that may help in energy production and improve heart muscle function.
4. **Magnesium**: A mineral important for heart rhythm regulation.
5. **Taurine**: An amino acid that can help in stabilizing cell membranes and might benefit heart function.

Always consult healthcare professionals before starting any new nutraceutical regimen, especially for managing genetic conditions like DCM1A.
Peptides: Dilated Cardiomyopathy 1A (DCM1A) is a genetic form of dilated cardiomyopathy primarily linked to mutations in the *LMNA* gene. Peptides related to this condition are not specifically standard treatment or diagnostic tools. Nanotechnology applications in DCM1A are currently in experimental stages, targeting better drug delivery systems and potentially gene-editing solutions. For precise information, consulting the latest research is recommended.